CCS
VRDN icon

Concentric Capital Strategies’s Viridian Therapeutics VRDN Stock Holding History

Concentric Capital Strategies’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-88,527
Closed -$1.7M – 311
2024
Q4 		$1.7M Buy
+88,527
New +$1.92M 0.08% 187

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Concentric Capital Strategies's VRDN Position: Q1 2025 in Review

Concentric Capital Strategies sold out of Viridian Therapeutics (VRDN) in Q1 2025, closing a stake of 88,527 shares — an estimated $1.7M sold.

Concentric Capital Strategies first reported a position in VRDN in Q4 2024 and held it in 1 quarter. The position peaked at $1.7M in Q4 2024. 176 funds tracked by Wall St. Rank hold VRDN as of Q1 2025.

  • Concentric Capital Strategies reported no remaining Viridian Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Concentric Capital Strategies sold 88,527 Viridian Therapeutics shares in Q1 2025, an estimated $1.7M.
  • Concentric Capital Strategies first reported a position in Viridian Therapeutics in Q4 2024 and held it in 1 quarter.
  • Concentric Capital Strategies's Viridian Therapeutics position peaked at $1.7M in Q4 2024.
  • 176 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2025.

Based on Concentric Capital Strategies's 13F filing for Q1 2025, filed 15 May 2025.